SCHEMBL9516082

SCHEMBL9516082

Cc1occc(=O)c1OC(=O)c1ccccc1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.52
HPGD P15428 3/20 0.47
HSD17B10 Q99714 3/20 0.47
ALOX15 P16050 1/20 0.47
LMNA P02545 4/20 0.47
GAA P10253 1/20 0.47
TSHR P16473 1/20 0.46
KMT2A Q03164 3/20 0.44
KDM4E B2RXH2 2/20 0.44
MEN1 O00255 2/20 0.44
MAPT P10636 1/20 0.44
HTT P42858 1/20 0.44
ATM Q13315 1/20 0.44
ALDH1A1 P00352 1/20 0.44
LDHA P00338 3/20 0.42
NPC1 O15118 1/20 0.40
PKM P14618 1/20 0.40
RAB9A P51151 1/20 0.40
TDP1 Q9NUW8 2/20 0.40
CTDSP1 Q9GZU7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31113429 1.00 SMN1; SMN2 (0.52) SMN1; SMN2HPGDHSD17B10ALOX15LMNA
SCHEMBL1193595 0.82 HSD17B10 (0.54) SMN1; SMN2HPGDHSD17B10LMNAGAA
SCHEMBL31113422 0.82 HSD17B10 (0.54) SMN1; SMN2HPGDHSD17B10LMNAGAA
SCHEMBL9721396 0.81 SMN1; SMN2 (0.63) SMN1; SMN2LMNAGAAKMT2AKDM4E
SCHEMBL18620487 0.76 SMN1; SMN2 (0.68) SMN1; SMN2LMNAGAAKMT2AKDM4E
SCHEMBL1845901 0.75 SMN1; SMN2 (0.55) SMN1; SMN2HPGDHSD17B10LMNAGAA
SCHEMBL9304475 0.73 HSD17B10 (0.58) SMN1; SMN2HPGDHSD17B10ALOX15LMNA
SCHEMBL17221047 0.73 SMN1; SMN2 (0.57) SMN1; SMN2HPGDLMNAGAAKMT2A
SCHEMBL15810341 0.73 SMN1; SMN2 (0.57) SMN1; SMN2HPGDLMNAGAAKMT2A
SCHEMBL18620878 0.72 SMN1; SMN2 (0.81) SMN1; SMN2HPGDHSD17B10ALOX15LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250161182-A1 ANTIMICROBIAL COMPOSITIONS BIO-ACTIVES SYNERGIO LTD (IL) 2025-05-22 US claimed
EP-4469037-A1 ANTIMICROBIAL COMPOSITIONS Bio-Actives Synergio Ltd (IL) 2024-12-04 EP claimed
WO-2023144808-A1 ANTIMICROBIAL COMPOSITIONS BIO-ACTIVES SYNERGIO LTD (IL) 2023-08-03 WO claimed
EP-2931715-B1 3-HYDROXY-4-OXO-4H-PYRANE OR 3-HYDROXY-4-OXO-1,4-DIHYDRO-PYRIDINE DERIVATIVES AS PROTEIN-ADHESIVE ACTIVE AGENTS MERCK PATENT GMBH (DE) 2016-12-21 EP claimed
US-20150306002-A1 3-HYDROXY-4-OXO-4H-PYRAN- OR 3-HYDROXY-4-OXO-1,4-DIHYDROPYRIDINE DERIVATIVES AS PROTEIN-ADHESIVE ACTIVE SUBSTANCES MERCK PATENT GMBH (DE) 2015-10-29 US claimed
EP-2931715-A1 3-HYDROXY-4-OXO-4H-PYRAN- OR 3-HYDROXY-4-OXO-1,4-DIHYDROPYRIDINE DERIVATIVES AS PROTEIN-ADHESIVE ACTIVE SUBSTANCES Merck Patent GmbH (DE) 2015-10-21 EP claimed
WO-2014090363-A1 3-HYDROXY-4-OXO-4H-PYRAN- OR 3-HYDROXY-4-OXO-1,4-DIHYDROPYRIDINE DERIVATIVES AS PROTEIN-ADHESIVE ACTIVE SUBSTANCES MERCK PATENT GMBH (DE) 2014-06-19 WO claimed
US-20250161182-A1 ANTIMICROBIAL COMPOSITIONS BIO-ACTIVES SYNERGIO LTD (IL) 2025-05-22 US disclosed
EP-4469037-A1 ANTIMICROBIAL COMPOSITIONS Bio-Actives Synergio Ltd (IL) 2024-12-04 EP disclosed
WO-2023144808-A1 ANTIMICROBIAL COMPOSITIONS BIO-ACTIVES SYNERGIO LTD (IL) 2023-08-03 WO disclosed
EP-2931715-B1 3-HYDROXY-4-OXO-4H-PYRANE OR 3-HYDROXY-4-OXO-1,4-DIHYDRO-PYRIDINE DERIVATIVES AS PROTEIN-ADHESIVE ACTIVE AGENTS MERCK PATENT GMBH (DE) 2016-12-21 EP disclosed
US-20150306002-A1 3-HYDROXY-4-OXO-4H-PYRAN- OR 3-HYDROXY-4-OXO-1,4-DIHYDROPYRIDINE DERIVATIVES AS PROTEIN-ADHESIVE ACTIVE SUBSTANCES MERCK PATENT GMBH (DE) 2015-10-29 US disclosed
EP-2931715-A1 3-HYDROXY-4-OXO-4H-PYRAN- OR 3-HYDROXY-4-OXO-1,4-DIHYDROPYRIDINE DERIVATIVES AS PROTEIN-ADHESIVE ACTIVE SUBSTANCES Merck Patent GmbH (DE) 2015-10-21 EP disclosed
WO-2014090363-A1 3-HYDROXY-4-OXO-4H-PYRAN- OR 3-HYDROXY-4-OXO-1,4-DIHYDROPYRIDINE DERIVATIVES AS PROTEIN-ADHESIVE ACTIVE SUBSTANCES MERCK PATENT GMBH (DE) 2014-06-19 WO disclosed
EP-0544681-A1 A NOVEL SALICYLIC ACID-MALTOL CONJUGATES. HAN BYUNG HOON (KR) 1993-06-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150306002-A1 3-HYDROXY-4-OXO-4H-PYRAN- OR 3-HYDROXY-4-OXO-1,4-DIHYDROPYRIDINE DERIVATIVES AS PROTEIN-ADHESIVE ACTIVE SUBSTANCES S100A4, CUTA, OCIAD1 SMN1; SMN2 4821/4885HPGD 361/4885HSD17B10 3186/4885
US-20250161182-A1 ANTIMICROBIAL COMPOSITIONS NOD2, PYCARD, CLPP SMN1; SMN2 4274/4885HPGD 2085/4885HSD17B10 1696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.